drospirenone estetrol

    Drospirenone/estetrol GudangMovies21 Rebahinxxi LK21

    Drospirenone/estetrol, sold under the brand name Nextstellis, among others, is a fixed-dose combination medication containing drospirenone, a progestin, and estetrol, an estrogen, which is used as a combined birth control pill for the prevention of pregnancy in women. It is taken by mouth.
    It was approved for medical use in Canada in March 2021, and in the United States in April 2021.


    Medical uses


    Drospirenone/estetrol is used as a combined birth control pill to prevent pregnancy in women.


    Side effects


    Estetrol-containing birth control pills, similarly to estradiol-containing birth control pills, may have a lower risk of venous thromboembolism (VTE) than ethinylestradiol-containing birth control pills based on studies of coagulation. However, it is likely that another decade will be required before post-marketing epidemiological studies of VTE incidence with these birth control pills are completed and able to confirm this.


    Pharmacology




    = Pharmacodynamics

    =
    Drospirenone/estetrol has a much lower impact on liver protein synthesis, including of sex hormone-binding globulin, angiotensinogen, and coagulation factors, than does ethinylestradiol/drospirenone.


    Society and culture




    = Legal status

    =
    Drospirenone/estetrol is approved for the use of hormonal contraception in the European Union, the United States, and Canada.


    = Brand names

    =
    Drospirenone/estetrol in sold under the brand names Nexstellis, Drovelis, and Lydisilka.


    See also


    Birth control pill formulations
    List of combined sex-hormonal preparations § Estrogens and progestogens


    References




    External links


    Clinical trial number NCT02817828 for "E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - EU/Russia Study" at ClinicalTrials.gov
    Clinical trial number NCT02817841 for "E4 FREEDOM (Female Response Concerning Efficacy and Safety of Estetrol/Drospirenone as Oral Contraceptive in a Multicentric Study) - United States/Canada Study" at ClinicalTrials.gov

Kata Kunci Pencarian: drospirenone estetrol

drospirenone estetroldrospirenone estetrol birth controldrospirenone estetrol 3-14.2drospirenone estetrol 3 mg 14.2 mgdrospirenone estetrol 3 14.2 mg tabletdrospirenone estetrol monohydratedrospirenone estetrol brand namedrospirenone estetrol nextstellisdrospirenone estetrol 3 mg 14.2 mg 28 tabestetrol drospirenone pill